Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Robert Peach(Bristol-Myers Squibb (United States)), Peter S. Linsley(Bristol-Myers Squibb (Germany)), Jürgen Bajorath(University of Bonn), JoAnne L. Greene(Bristol-Myers Squibb (United States)), Joseph Naemura(Bristol-Myers Squibb (United States)), William Brady(Bristol-Myers Squibb (United States)), Gina Leytze(Bristol-Myers Squibb (United States))
Cited by 246
Related Papers
Docking and scoring in virtual screening for drug discovery: methods and applications
|Nature Reviews Drug Discovery|2004|4k
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Polypharmacology: Challenges and Opportunities in Drug Discovery
|Journal of Medicinal Chemistry|2014|1.1k
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
|Immunity|1994|971
Integration of virtual and high-throughput screening
|Nature Reviews Drug Discovery|2002|940